Table 1.

Cell cycle distribution of HCT-15 and HT-29 cells after treatment with various concentrations of 5-FU, celecoxib and 5-FU and celecoxib

HCT-15		SubG1 (%)	G0/G1 (%)	S (%)	G2/M (%)
Control		2.75	51.94	14.61	30.90
5-FU	10-6 mol/L	2.49	37.35	18.93	41.40
	10-5 mol/L	2.97	0.91	11.25	84.96
	10-4 mol/L	2.77	0.26	27.09	70.13
	10-3 mol/L	43.33	15.93	20.54	20.55
Celecoxib	10-7 mol/L	1.95	42.00	17.54	38.87
	10-6 mol/L	4.14	58.80	15.85	21.60
	10-5 mol/L	1.70	37.45	15.96	45.32
	10-4 mol/L	31.99	7.45	33.10	27.67
5-FU (10-3 mol/L) & Celecoxib	10-7 mol/L	3.88	0.46	14.48	81.43
	10-6 mol/L	4.18	0.56	32.86	62.73
	10-5 mol/L	40.46	6.95	28.35	24.55
HT-29		SubG1 (%)	G0/G1 (%)	S (%)	G2/M (%)
Control		2.12	60.49	4.62	32.84
5-FU	10-6 mol/L	8.92	73.77	3.73	13.85
	10-5 mol/L	17.51	62.56	3.13	17.13
	10-4 mol/L	37.70	47.87	3.63	10.87
	10-3 mol/L	68.27	25.69	1.68	4.61
Celecoxib	10-7 mol/L	8.29	62.37	6.11	23.53
	10-6 mol/L	9.66	60.02	7.24	23.29
	10-5 mol/L	9.68	60.69	6.39	23.44
	10-4 mol/L	26.10	54.30	4.02	15.76
5-FU (10-3 mol/L) & Celecoxib	10-7 mol/L	18.78	69.39	1.89	9.99
	10-6 mol/L	36.15	46.46	3.16	14.35
	10-5 mol/L	43.34	41.34	2.74	12.61